Pablo Menéndez

Founder and CSO

Pablo Menéndez was awarded a PhD by the University of Salamanca in 2002. He then conducted postdoctoral training (2002-2006) in stem cell biology and childhood leukemia. He returned to Granada as Director of The Andalusian Stem Cell Bank and Principal Investigator at GENyO, a Pfizer-Andalusian Health Department centre for Genomics and Oncology (2007-2013). Since July 2013 he is an ICREA Research Professor and he heads the "Stem cell biology, developmental leukemia and Immunotherapy" group at the Josep Carreras Leukemia Institute-Campus Clinic Hospital-School of Medicine of the University of Barcelona. Pablo Menendez has published 190 peer-review publications with an accumulated impact factor of 2100 (H and i10 factors are 61 and 160, respectively). His work has been cited 13000 times. He has obtained solid competitive national and international research funding, has filed 10 patents in stem cell biology and immunotherapy, and has supervised >30 scientific staff including master, PhD students, postdoctoral scientists and technicians

Linked in

Stefanos Theoharis

CEO

Stefanos, PhD, with more than 20 years of broad experience in the cell and gene therapy space, business development, program management, manufacturing and basic research brings a deep knowledge C&GT sector. Former CBO of Bone Therapeutics, Belgium-based company, developing specialized cell therapies for orthopaedic disorders. Pior to that he was Senior Vice-President at Cell Medica, and CBO at apceth GmbH. He also held positions as Head of Business Development at the antisense RNA drug specialist Antisense Pharma (now Isarna), and Director Business Development at Roche, focused on partnering activities in emerging science and technologies. Stefanos also worked at Lazard, the global investment bank, advising to a variety of life sciences firms on M&As and financing transactions.

Linked in

Antoni Garcia Prat

Manager of the Josep Carreras International Foundation against Leukemia

Graduate in Economic Sciences from the University of Barcelona. Master of Science Harvard University..

Linked in

Ignacio Prieto

Tech Transfer Funds Analyst in Clave Capital

Biomedical engineer, Universidad de Navarra and MBA applied to life sciences, Universidad de Barcelona. He began his professional career as a researcher in areas such as tissue engineering and cell aging. He has more than five years of experience in Venture Capital and Technology Transfer and currently, he is part of the board of directors of several biotech and healthtech companies.

Linked in

Joan Mercadal

Founder and Partner in NARA Health Capital

With a background in Biology, an MSc in Pharmacoepidemiology, and an MB. Started career in the Pharmaceutical Industry and later moved into entrepreneurship, founding and managing several research and clinical research ventures. Over time, experienced investor with track record of success in the healthcare industry. Since 2021 Founder & partner in Nara Health Capital.

Linked in

Laura Rodríguez

Principal Invivo Capital

Principal of Invivo Capital Partners. Background in Biotechnology with a PhD in Oncology field. Experience in Technology transfer at Vall d'Hebron (VHIR). Since 2018 she's been working in VC, in Healthequity and Invivo.

Linked in